Kellogg-Casepack-Cases - APPENDIX: Kellogg Consulting Club...

Info iconThis preview shows pages 1–4. Sign up to view the full content.

View Full Document Right Arrow Icon
Page 34 APPENDIX: Kellogg Consulting Club Practice Cases While most cases require multiple analytical techniques, the category indicates where the candidate will likely spend most of the time. SECTION I: Sample Case Interviews 1. New Drug Launch 2. Prozac SECTION II: Profitability/Operations 3. Shamrock Chemical 4. Chilled Beverages 5. Distilled Spirits 6. Commodity Manufacturer 7. Snack Food 8. Conglomerate ROIC Increase 9. Agricultural Equipment Manufacturing 10. Paint Manufacturer 11. Super Regional Bank 12. Local Banking Demand 13. Cement Manufacturer 14. Beverage Company 15. Candy Company SECTION III: Industry Analysis/Growth 16. Direct Mail Retailer 17. Selective Binding Case 18. Iberia Gasoline Pricing 19. Pipeline Company 20. Permanent Light Bulbs 21. Aluminum Can Manufacturer 22. Science Industry 23. Information Services Company 24. Meat Packing Industry 25. Video Games 26. Merger Candidate in Chemical Industry 27. Machine Loading Case 28. Telecommunications Diversification 29. Packaging Material Manufacturer
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Page 35 SECTION IV: Market Entry/Expansion/Investment 30. Corn Feed Company 31. Buenos Aires ENT 32. Consulting Firm (I) 33. Concrete Manufacturer 34. Healthcare Company 35. Gas Manufacturer 36. Vitamin Manufacturer Entry into China SECTION V: Market Sizing/Estimation/Brainteasers 37. Cigar Bar 38. New Magazine 39. Piano Tuners 40. Cars in the Chicago Loop 41. Chewing Gum Market 42. Golf ball Market Entry 43. Oil Refining Industry SECTION VI: Miscellaneous 44. Logging Company 45. Cure for Common Headaches 46. Chemical Sweetener Manufacturer 47. Austria Star Mobile Wireless Launch
Background image of page 2
Page 36 CASE 1: DRUG LAUNCH Category: Market Entry Analysis Question (posed by the interviewer): Our client is the U.S. pharmaceutical division of a multi-national corporation. In about six months the division will receive FDA approval to launch an anti-depressant drug. Despite this apparent good news from the FDA, the U.S. division is not elated. It has concerns over the market potential for this drug and its ability to reach the key prescribers in this therapeutic category. How would you help them decide whether to 1) launch alone, 2) co-market with a partner, or 3) sell, license or swap the drug to a third party. Information to be given if asked: Market Conditions ±² The concerns over market potential center on whether the drug can gain adequate competitive advantage in a market segment having two dominant, patent-protected competitors and nearly 100 generic competitors. Additionally, a competitor recently introduced a higher technology antidepressant, which appears to offer therapeutic advantages. Firm Conditions ±² Gaining the professional endorsement of psychiatrists is crucial to success in this therapeutic category since they write approximately half of the prescriptions for antidepressants. However, the division has no experience marketing drugs to this physician group. Consequently, it would have to hire a sales force and/or enter into a co- marketing agreement to gain access to psychiatrists through someone else’s force. The client would be able to
Background image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 4
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 08/02/2011 for the course ECON 101 taught by Professor Na during the Spring '03 term at Kellogg School of Management.

Page1 / 72

Kellogg-Casepack-Cases - APPENDIX: Kellogg Consulting Club...

This preview shows document pages 1 - 4. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online